الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Pterygium is a fibrovascular lesion of the ocular surface that can display an aggressive clinical behavior and, occasionally, threatens vision. Although there is no consensus on its pathogenesis, recent evidence suggests that it is a proliferative, rather than degenerative condition, strongly correlated with exposure to ultraviolet radiation (UVR) of solar light.
There is a worldwide distribution of pterygium, but it is more common in warm, dry climates.
Many surgical procedures had been described for treatment of pterygium; the main complication of these procedures is recurrence rate, estimated as high as 30% to 90%.
Adjuvant therapy, including antimetabolites and radiation therapy had succeeded in diminishing the number of recurrences. However, serious complications were associated with these methods of treatment. Thus, it is important to choose the safe method.
Angiogenesis is essential for new blood vessels formation, tumor growth and metastasis. As researchers gained a greater understanding of VEGF and its role in angiogenesis, they turned their focus to creating therapies that could interfere with angiogenesis by targeting the VEGF protein, one of the most potent and predominant regulators of angiogenesis.
Bevacizumab (Avastin, Genentech Inc., San Francisco, USA) is a full-length, humanized, monoclonal antibody against all types of VEGF. It binds to and neutralizes the biologic activity of human VEGF, thus